Buscador de publicaciones

Publicaciones

  • Gargallo P, Bautista F, Juan-Ribelles A, Izquierdo E, Soriano A, de Rojas T, Escudero A, Lavarino C, Solano P, Hladun R, Rubio-San-Simón A, Martínez-Romera I, Calabria I, Gene-Olaciregui N, Castañeda-Heredia A, de Álava E, Pérez-Martínez A, Astigarraga I, Patiño-García A, Alonso J, Fernández-Teijeiro A, Cañete A and Moreno L.

    Current status of precision medicine in pediatric oncology in Spain: a consensus report by the Spanish Society of Paediatric Haematology and Oncology (SEHOP).

    CLINICAL & TRANSLATIONAL ONCOLOGY . 24(5): 809-815.

    [doi:10.1007/s12094-021-02759-7]

  • Gonçalves-Alves EC, Garcia-López M, Gomez-Gonzalez S, Ecker RC, Suñol M, Muñoz-Aznar O, Carcaboso AM, Mora J, Lavarino C and Mateo-Lozano S.

    AC-265347 Inhibits Neuroblastoma Tumor Growth by Induction of Differentiation without Causing Hypocalcemia.

    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES . 23(8): 4323.

    [doi:10.3390/ijms23084323]

  • Alcon C, Martín F, Prada-Varela E, Mora J, Soriano A, Guillén G, Gallego S, Roma J, Samitier J, Villanueva A and Montero J.

    MEK and MCL-1 sequential inhibition synergize to enhance rhabdomyosarcoma treatment.

    Cell Death Discovery . 8(1): 172-172.

    [doi:10.1038/s41420-022-00959-w]

  • Castañeda-Heredia A, Maite Gorostegui Obanos, Miralles SL, ALICIA CHAMIZO BREMER, Patiño SC, Flores MA, Garraus-Oneca M, Lazaro JJ, Santa-María López V, Varo A, Muñoz JP and Mora J.

    How we approach the treatment of patients with high-risk neuroblastoma with naxitamab: experience from the Hospital Sant Joan de Déu in Barcelona, Spain.

    ESMO Open . 7(2): 100462-100462.

    [doi:10.1016/j.esmoop.2022.100462]

  • García-Domínguez DJ, Hajji N, López-Alemany R, Sánchez-Molina S, Figuerola-Bou E, Morón Civanto FJ, Rello-Varona S, Andrés-León E, Benito A, Keun HC, Mora J, Tirado ÓM, de Álava E and Hontecillas-Prieto L.

    Selective histone methyltransferase G9a inhibition reduces metastatic development of Ewing sarcoma through the epigenetic regulation of NEU1.

    Oncogene . 41(18): 2638-2650.

    [doi:10.1038/s41388-022-02279-w]

  • Inarejos E, Navarro OM, Navallas M, Enrique Ladera Gonzalez, Torner-Rubies F, Suñol M, Garraus-Oneca M, March JC and Ignacio Barber Martínez de la Torre.

    Multiparametric MRI evaluation of bone sarcomas in children.

    Insights into Imaging . 13(1): 33-33.

    [doi:10.1186/s13244-022-01177-9]

  • Pascual-Pastó G, Castillo-Ecija H, Unceta N, Aschero R, Resa-Pares C, Gómez-Caballero A, Vilà-Ubach M, Muñoz-Aznar O, Suñol M, Burgueño V, Gomez-Gonzalez S, Sosnik A, Ibarra M, Schaiquevich P, de Álava E, Tirado OM, Mora J and Carcaboso AM.

    SPARC-mediated long-term retention of nab-paclitaxel in pediatric sarcomas.

    JOURNAL OF CONTROLLED RELEASE . 342: 81-92. Nº de citas: 1

    [doi:10.1016/j.jconrel.2021.12.035]

  • Mesegue Meda M, Alonso-Saladrigues A, Pérez-Jaume S, Comes-Escoda A, José Luis Dapena Díaz, Faura A, Conde Cuevas N, Català-Temprano A, Ruiz-Llobet A, Zapico-Muñiz E, Camós-Guijosa M and Rives-Sola S.

    Lower incidence of clinical allergy with PEG-asparaginase upfront versus the sequential use of native E. coli asparaginase followed by PEG-ASP in pediatric patients with acute lymphoblastic leukemia.

    HEMATOL ONCOL . 39(5): 687-696.

    [doi:10.1002/hon.2914]

  • Rubio-San-Simón A, Hladun Alvaro R, Juan Ribelles A, Castañeda-Heredia A, Guerra-García P, Verdú-Amorós J, Andrés M, Cañete A, Rives-Sola S, Pérez-Martínez A, Mora J, Patiño-García A, Lassaleta A, Llort A, Ramírez M, Mata C, Gallego S, Martín-Broto J, Cruz-Martínez O, Morales-La Madrid A, Solano P, Martínez Romera I, Fernández-Teijeiro A, Bautista F and Moreno L.

    The paediatric cancer clinical research landscape in Spain: a 13-year multicentre experience of the new agents group of the Spanish Society of Paediatric Haematology and Oncology (SEHOP).

    CLINICAL & TRANSLATIONAL ONCOLOGY . 23(12): 2489-2496.

    [doi:10.1007/s12094-021-02649-y]

  • Coltin H, Sundaresan L, Smith KS, Skowron P, Massimi L, Eberhart CG, Schreck KC, Gupta N, Weiss WA, Tirapelli D, Carlotti C, Li KKW, Ryzhova M, Golanov A, Zheludkova O, Absalyamova O, Okonechnikov K, Stichel D, von Deimling A, Giannini C, Raskin S, Van Meir EG, Chan JA, Fults D, Chambless LB, Kim SK, Vasiljevic A, Faure-Conter C, Vibhakar R, Jung S, Leary S, Mora J, McLendon RE, Pollack IF, Hauser P, Grajkowska WA, Rubin JB, van Veelen MC, French PJ, Kros JM, Liau LM, Pfister SM, Kool M, Kijima N, Taylor MD, Packer RJ, Northcott PA, Korshunov A and Ramaswamy V.

    Subgroup and subtype-specific outcomes in adult medulloblastoma.

    ACTA NEUROPATHOLOGICA . 142(5): 859-871.

    [doi:10.1007/s00401-021-02358-4]